21 completed, 9 terminated, 4 withdrawn. 17 Phase 1, 12 Phase 2, 5 Not applicable, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 11, Terminated 5, Withdrawn 1 |
| Phase 2 | 12 | Completed 5, Terminated 4, Withdrawn 3 |
| Not applicable | 5 | Completed 4, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Stage IVA Colon Cancer: new trials by email Literature Review of Stage IVA Colon Cancer trials Research Report on Stage IVA Colon Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Binimetinib, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 | Terminated | University of California, San Francisco | 2 | 2020-08-31 | 2023-01-09 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer Quality-of-Life Assessment, Questionnaire Administration - Stage IVA Colon Cancer, Stage IVA Rectal Cancer | Completed | SWOG Cancer Research Network | 380 | 2016-06-22 | 2023-01-26 | |
| Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver irinotecan-eluting beads, hepatic artery embolization - Liver Metastases, Mucinous Adenocarcinoma of the Colon | Phase 1 | Terminated | Fox Chase Cancer Center | 2 | 2016-01-29 | 2018-02-26 |
| Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer Capecitabine, Laboratory Biomarker Analysis, Nintedanib - Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2015-05-08 | 2021-07-08 |
| Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer ziv-aflibercept, leucovorin calcium, fluorouracil - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Withdrawn | University of Southern California | 2015-03-01 | 2015-05-06 | |
| CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery 6,8-bis(benzylthio)octanoic acid, fluorouracil, pharmacological study - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 1 | Completed | Wake Forest University Health Sciences | 19 | 2015-01-06 | 2023-08-07 |
| Programs to Support You During Chemotherapy (Pro-You) Yoga Skills Training (YST), questionnaire administration, fatigue and depressive symptom assessment and management - Depressive Symptoms, Fatigue | Not applicable | Completed | Vanderbilt-Ingram Cancer Center | 3 | 2014-08-01 | 2015-06-23 |
| MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer MEK inhibitor MEK162, leucovorin calcium, fluorouracil - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | City of Hope Medical Center | 26 | 2014-07-16 | 2026-10-19 |
| Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy ziv-aflibercept, leucovorin calcium, irinotecan hydrochloride - Recurrent Colon Cancer, Recurrent Rectal Cancer | Not applicable | Withdrawn | City of Hope Medical Center | 2014-01-01 | 2014-07-21 | |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers educational intervention, telephone-based intervention, quality-of-life assessment - Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter | Not applicable | Completed | City of Hope Medical Center | 200 | 2013-10-29 | 2026-10-01 |
| Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors cytology specimen collection procedure, laboratory biomarker analysis - Recurrent Breast Cancer, Recurrent Colon Cancer | Completed | Ohio State University Comprehensive Cancer Center | 150 | 2013-09-03 | 2021-10-28 | |
| PET-MRI in Diagnosing Patients With Colon or Rectal Cancer positron emission tomography, computed tomography, magnetic resonance imaging - Recurrent Colon Cancer, Recurrent Rectal Cancer | Not applicable | Completed | Case Comprehensive Cancer Center | 15 | 2013-04-01 | 2021-05-18 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study - Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2013-03-01 | 2019-09-20 |
| A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy - Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma | Phase 2 | Terminated | University of Washington | 27 | 2013-03-01 | 2018-01-16 |
| Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors selumetinib, cetuximab, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2012-10-01 | 2014-05-29 |
| Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies oxaliplatin, irinotecan hydrochloride, leucovorin calcium - Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder | Phase 1 | Completed | University of Chicago | 79 | 2012-03-26 | 2020-05-08 |
| Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer Bevacizumab, Fluorouracil, Irinotecan Hydrochloride - Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2011-08-01 | 2017-04-19 |
| Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer linifanib - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 30 | 2011-06-01 | 2014-08-26 |
Showing 20 of 34. Sign in to see all of them.
Colonic Neoplasms (34) · Rectal Neoplasms (33) · Pancreatic Neoplasms (6) · Breast Neoplasms (5) · Carcinoma, Renal Cell (5) · Carcinoma, Non-Small-Cell Lung (4) · Brain Neoplasms (3) · Breast Neoplasms, Male (3) · Melanoma (3) · Stomach Neoplasms (3) · Colorectal Neoplasms (2) · Esthesioneuroblastoma, Olfactory (2) · Glioblastoma (2) · Gliosarcoma (2) · Ovarian Neoplasms (2)
Colonic Diseases (34) · Digestive System Diseases (34) · Digestive System Neoplasms (34) · Gastrointestinal Diseases (34) · Gastrointestinal Neoplasms (34) · Intestinal Diseases (34) · Intestinal Neoplasms (34) · Neoplasms (34) · Neoplasms by Site (34) · Rectal Diseases (33) · Colorectal Neoplasms (32) · Carcinoma (6) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6) · Neoplasms by Histologic Type (6)
Fluorouracil (13) · Leucovorin (10) · Irinotecan (8) · Oxaliplatin (8) · Bevacizumab (6) · Cetuximab (5) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (3) · Capecitabine (3) · Fluorodeoxyglucose F18 (2) · aflibercept (2) · binimetinib (2) · cediranib (2) · dehydroftorafur (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · 4-phenylbutyric acid (1)
National Cancer Institute (NCI) (14) · City of Hope Medical Center (4) · Fox Chase Cancer Center (2) · Roswell Park Cancer Institute (2) · Vanderbilt-Ingram Cancer Center (2) · Case Comprehensive Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1) · Sanjiv Sam Gambhir (1) · Stanford University (1) · University of California, San Francisco (1) · University of Chicago (1) · University of Southern California (1) · University of Washington (1) · Wake Forest University Health Sciences (1)
United States (33) · Canada (1)
Marwan Fakih (2) · Afsaneh Barzi (1) · April Eichler (1) · Barbara Burtness (1) · Betty Ferrell (1) · Caio Rocha Lima, MD (1) · Chloe E Atreya, MD, PhD (1) · Christos Fountzilas (1) · Edmund Kopetz (1) · Efrat Dotan (1) · Emily Chan (1) · Hedy Kindler (1) · Henry Pitot (1) · Jeffrey Wong (1) · Joleen Hubbard (1)
PMID 25965900, PMID 26062933, PMID 26611425, PMID 30850872, PMID 32375690, PMID 34749008, PMID 35771552, PMID 38697618
P30CA016056 (2), P30CA068485 (2), N01CM00039 (1), N01CM00100 (1), N01CM17101 (1), N01CM17102 (1), N01CM17103 (1), N01CM17105 (1), N01CM62206 (1), P01CA043904 (1), P30CA006927 (1), P30CA012197 (1), P30CA014089 (1), P30CA014520 (1), P30CA015083 (1)